ReviewBreast cancer (Dove Medical Press)2014
Recent advances in the development of breast cancer vaccines.
Review in Breast cancer (Dove Medical Press), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 23 citations in OpenAlex.
- Breast cancer vaccines: from immune promise to the prospect of eradication.Annals of medicine and surgery (2012) · 2025Article
- Integrative Analysis of Novel Ferroptosis-Related Genes Signatures as Prognostic Biomarkers in Ovarian Cancer.Cancer reports (Hoboken, N.J.) · 2025Article
- Tumor-Derived Lactate Creates a Favorable Niche for TumorFrontiers in cell and developmental biology · 2022Review
- Penetrable Nanoplatform for "Cold" Tumor Immune Microenvironment Reeducation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2020Article
- Extracellular Vesicle-MediatedMolecular cancer therapeutics · 2020Article
- The influence of microenvironment on tumor immunotherapy.The FEBS journal · 2019Review
- Immunooncology in Breast Cancer: Active and Passive Vaccination Strategies.Breast care (Basel, Switzerland) · 2018Review
- Immunotherapy for Breast Cancer: Current and Future Strategies.Current surgery reports · 2017Article
- Fuzheng Qingjie Granules Inhibit Growth of Hepatoma Cells via Inducing Mitochondria-Mediated Apoptosis and Enhancing Immune Function.Integrative cancer therapies · 2017Article
- Article
- Adaptive immunity programmes in breast cancer.Immunology · 2017Review
- Immune effect and safety evaluation of vaccine prepared by dendritic cells modified by rAAV-carrying BCSG1 gene.Gene therapy · 2016Article
- Antigenic variability: Obstacles on the road to vaccines against traditionally difficult targets.Human vaccines & immunotherapeutics · 2016Review
- Immune profiling in human breast cancer using high-sensitivity detection and analysis techniques.JRSM open · 2015Article
- Breast Cancer Update 2014 - Focus on the Patient and the Tumour.Geburtshilfe und Frauenheilkunde · 2015Article
- Subverting Subversion: A Review on the Breast Cancer Microenvironment and Therapeutic Opportunities.Breast cancer : basic and clinical research · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The manipulation of the immune system through the administration of a vaccine to direct an effective and long-lasting immune response against breast cancer (BC) cells is an attractive strategy. Vaccines would have several theoretical advantages over standard therapies, including low toxicities, high specificity, and long-lasting efficacy due to the establishment of immunological memory. However, BC vaccines have failed to demonstrate meaningful results in clinical trials so far. This reflects the intrinsic difficulty in breaking the complex immune-escaping mechanisms developed by cancer cells. New vaccines should be able to elicit complex immunologic response involving multiple immune effectors such as cytotoxic and antibody-secreting B cells, innate immunity effectors, and memory cells. Moreover, especially in patients with large tumor burdens and metastatic disease, combining vaccines with other strategies, such as systemic BC therapies, passive immunotherapy, or immunomodulatory agents, could increase the effectiveness of each approach. Here, we review recent advances in BC vaccines, focusing on suitable targets and innovative strategies. We report results of most recent trials investigating active immunotherapy in BC and provide possible future perspectives in this field of research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.